Care Access Research LLC

1. Eli Lilly and Company $73,516,805 794 payments
2. Pfizer Inc. $6,572,621 44 payments
3. Sanofi US Services Inc. $5,349,022 578 payments
4. AbbVie, Inc. $2,203,015 556 payments
5. Allergan Inc. $663,309 175 payments
6. Otsuka Pharmaceutical Development & Commercialization, Inc. $335,795 13 payments
7. Janssen Research & Development, LLC $306,048 71 payments
8. Incyte Corporation $217,433 223 payments
9. Ucb SA $160,793 16 payments
10. Genentech, Inc. $139,658 31 payments

1. A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease $14,534,748 81 payments
2. A Donanemab (Ly3002813) Prevention Study in Participants With Alzheimer's Disease (Trailblazer-Alz 3) $10,604,423 33 payments
3. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(A) Who Have Established Atherosclerotic Cardiovascular Disease Or Are at Risk for A First Cardiovascular Event - Acclaim-Lp(A) $6,829,416 49 payments
4. A Phase 3 Multicenter Placebocontrolled Randomized Observerblinded Trial to Evaluate the Efficacy Safety Tolerability Immunogenicity and Lot Consistency of A 6Valent Ospabased Lyme Disease Vaccine in Healthy Participants 5 Years of Age $6,546,577 24 payments
5. A Phase 3 Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Ly3819253 in Preventing Sars Cov 2 Infection and Covid 19 in Skilled Nursing and Assisted Living Facility Residents and Staff A Niaid and Lilly Collaborative Study $6,307,412 24 payments
6. A Study of Remternetug Versus Placebo in Early Alzheimer's Disease Participants at Risk for Cognitive and Functional Decline $3,729,845 35 payments
7. A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease $3,417,897 34 payments
8. Assessment of Safety, Tolerability, and Efficacy Measured By Amyloid Reduction of Ly3372993 in Early Symptomatic Alzheimer's Disease $3,029,481 5 payments
9. Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) $2,903,192 323 payments
10. A Randomized, Double Blind, Placebo Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Ly3819253 and Ly3832479 in Participants With Mild to Moderate Covid-19 Illness $2,715,190 11 payments

1. Patient care $19,615 3 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.